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The  antimicrobial  activity  of  the  myrsinoic  acid A  isolated  from  Myrsine  coriacea  (Sw.)  R.Br.  ex Roem.
&  Schult.,  Primulaceae,  and  a  two semi-synthetics  derivatives  was  tested  against  Bacillus  subtilis,
Escherichia  coli,  Salmonella  enterica  subsp.  enterica  serovar  typhi,  Staphylococcus  aureus,  Streptococcus  pyo-
genes, Pseudomonas  aeruginosa,  Micrococcus  luteus,  Candida  albicans,  Candida  krusei  and  Candida  tropicalis.eywords:
yrsine coriace
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yrsinoic acid A
The  microdilution  method  was  used  for  the  determination  of the  minimum  inhibitory  concentration  dur-
ing evaluation  of  the  antimicrobial  activity.  The  myrsinoic  acid  A  showed  no  activity  against  the  selected
microorganisms  but the  hydrogenated  and  acetylated  derivatives  were  active  against  B. subtilis,  E. coli,  S.
aureus and  P. aeruginosa.
©  2015  Sociedade  Brasileira  de  Farmacognosia.  Published  by Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
Bacterial infectious diseases are a serious worldwide public
ealth problem. The increase in bacterial resistance and the rapid
mergence of new infections have drastically decreased the efﬁ-
acy of the drugs employed in the treatment of pathologies caused
y certain microorganisms (Hemaiswarya et al., 2008). The prob-
em of microbial resistance is growing and the future prospect of
he use of antimicrobial drugs is uncertain. It has become urgent
o adopt, therefore, measures to tackle the problem, including the
ontrol of the use of antibiotics and studies on new natural and
ynthetic drugs (Nascimento et al., 2000).
The plant Myrsine coriacea (Sw.) R.Br. ex Roem. & Schult.
s owned by the family Primulaceae and gender Myrsine, char-
cterized by alquilbenziquinonas and triterpenoids, the plants
f this genus are known as capororoca, and several studies
ave reported biological activities such as cytotoxic, contra-
eptive, biocidal, anti-spermatogenic, antiseptic, antibacterial,
nti-inﬂammatory, antioxidant, antiplasmodial, and against dia-
etes mellitus (Bagalwa and Chifundera, 2007; Bhandari et al.,
∗ Corresponding author.
E-mail: djbf@ufscar.br (J.B. Fernandes).
http://dx.doi.org/10.1016/j.bjp.2015.07.023
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora2008; Cordero et al., 2004; Gathuama et al., 2004; Januário et al.,
1991, 1992; Katuura et al., 2007; Reguero et al., 1989).
Several natural products of plants have been used as basic struc-
tures for the synthesis and development of new drugs, so the
natural products have been used as starting to select lead com-
pounds for optimization.
This study was  conducted to determine the in vitro antimicrobial
activity of myrsinoic acid A from the plant M. coriacea, and their
derivatives.
Materials and methods
Plant material
Myrsine coriacea (Sw.) R.Br. ex Roem. & Schult., Primulaceae,
was collected at the Cerrado of the Universidade Estadual de Goiás,
Anápolis, Goiás, Brazil and identiﬁed by Dra Maria de Fatima Freitas,
UFRJ, Brazil and previous as Myrsine cuneifolia by Dr. Mirley Luciene
dos Santos, UEG, Brazil (Burger et al., 2012). Voucher specimens
(4215) was deposited in the Herbarium of the same University.Extraction, isolation and reactions
In previous work, Burger et al. (2012) isolated myrsinoic acid
A (1) from fruits ethanolic extract of the M. coriacea and this
 Ltda. All rights reserved.
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ompound was submitted to hydrogenation reaction yielding the
ompound 2. The compound 3 was obtained by acetylation reaction
f compound 1. The purity of compounds 1, 2 and 3 was  determined
y TLC and analyzed of their 1H NMR  spectrum and no contamina-
ion and by-products was detected.
ydrogenation reaction conditions
Myrsinoic A acid (1) (0.02 g) was solubilized in 4 ml  of methanol,
nd added 0.01 g of palladium–carbon (Pd–C), and allowed to con-
act with hydrogen gas for 12 h under constant agitation, after this
ime the solution was ﬁltered with celite, the solvent was  evapo-
ated and was obtained 0.017 g (85%) of 2.
cetylation reaction conditions
Myrsinoic A acid (1) (0.02 g) was solubilized in 1 ml  of pyridine
nd added 1 ml  of acetic anhydride, and the reaction was agitated
uring 24 h. After, 3 ml  of distillated water was added to the solu-
ion and was extracted with chloroform (5 ml)  and this extract was
ashed with HCl (10%, 3 ml), followed by drying with magnesium
ulfate, yielding 0.021 g (95%) of 3.
ntimicrobial assay
Antimicrobial assays were performed using the broth microdi-
ution technique proposed by the Clinical and Laboratory Standards
nstitute (CLSI) 21 M7-A6 and adaptation of the M27-A2, for deter-
ining the MIC  (lowest concentration able to inhibit the growth
f microorganisms). The MIC  determinations were performed in
riplicate in microplates with 96 wells. The microorganisms used
ere from American Type Culture Collection of Bacillus subtilis
ATCC 6623), Escherichia coli (ATCC 25922), Salmonella enterica
ubsp. enterica serovar typhi ATCC 6539, Staphylococcus aureus
ATCC 25923), Streptococcus pyogenes ATCC 19615, Pseudomonas
eruginosa (ATCC 15442), Micrococcus luteus ATCC 9341, Candida
lbicans (ATCC 10231), Candida krusei ATCC 6258, and Candida
ropicalis ATCC 28707. The stock solutions of tested samples were
repared in vial like Eppendorf solubilizing 1 mg  of sample in 40 l
f dimethyl sulfoxide (DMSO). These solutions were diluted in
60 l of Mueller–Hinton broth for bacteria or Sabouraud broth
or testing with yeast. Solutions with the ﬁnal concentrations ran-
ing from 7.81 to 500 g/ml were prepared. The inoculums were
tandardized based on a scale of 0.5 McFarland turbidity standard
108 CFU/ml) and diluted at 1:10 ratio to the broth microdilu-
ion procedure. After micropipetting, microplates were capped and
ncubated at 37 ◦C for 18–24 h without agitation. After the incuba-
ion period, the results were visualized and the wells that showed
o apparent growth were selected to determine the antimicrobial
ctivity of samples.
This determination was performed using subcultures in Petri
ishes using Mueller–Hinton agar for growing bacteria and
abouraud agar for the fungus growth. The Petri dishes were
ncubated at 37 ◦C for 48 h and veriﬁed the presence/absence of
icrobial colonies. After preparation of subcultures, were added to
ach well of the microplates, 15 l of resazurin to 0.01% in ster-
le aqueous solution which, after 4 h of reincubation, the reading
as performed. Thus, it was possible to determine the low-
st concentration of each extract that can inhibit the growth of
icroorganisms through indicators in diluted solution.
All tests were performed with negative control (DMSO), growth
ontrol of the microorganisms and control of precipitation of the
ample, avoiding possible false-negative or false-positive.de Farmacognosia 25 (2015) 451–454
Results and discussion
The compound 1 (myrsinoic A acid) from M.  coriacea fruits
ethanolic extract was  submitted a catalytic hydrogenation and
acetylation reactions to obtain two  semi-synthetic derivatives
2 and 3. Myrsinoic acid A (1) and the derivatives 2 and 3
were identiﬁed through 1H and 13C NMR, experiments in one
dimensions (400 MHz, CDCl3, Burger et al., 2012) in compar-
ison with literature (Table 1, Cruz et al., 2013; Dong et al.,
1999).
Compounds 1–3 were assayed in inhibition of B. subtilis,  E. coli,
S. enterica subsp. enterica serovar typhi, S. aureus,  S. pyogenes, P.
aeruginosa,  M.  luteus,  C. albicans, C. krusei and C. tropicalis and
reported here, by the ﬁrst time, the effect of these compounds on
the microorganisms tested.
The myrsinoic acid A showed no activity against the selected
microorganisms but the derivatives, 2 and mainly 3, were active
against B. subtilis,  E. coli, S. aureus and P. aeruginosa,  results
including the positive controls are described in Table 2. Cruz
et al. (2013) had assayed myrsinoic acid A and it presented
minimal inhibitory concentration of 7.81, 31.25, 125, >1000 and
>1000 g/ml to B. subtilis (ATTC 23858), S. aureus (ATCC 6538P),
Staphylococcus saprophyticus (ATCC 35552), S. pyogenes (ATCC
27853), Gram-negative and Yeast, respectively and cytotoxicity
activity to brine shrimp test (BST, LC50 91.65 g/ml), murine
ﬁbroblast L929 cell, (L929, IC50 >100 g/ml) and Saccharomyces
cerevisiae strain XV185-14c (IC50 66.64 g/ml). Myrsionic acid
A also presents inhibitions to HB-EGF (heparin-binding epider-
mal  growth factor-like growth factor; involved in cancer disease;
Lee and Mandinova, 2011), to methioninase (l-methionine lyase;
involved in cancer disease and oral malodor; Itoh et al., 2014), to
acetylcholinesterase (related to Alzheimer disease; Gazoni, 2009;
Filippin et al., 2009), and anti-inﬂammatory activity (Dong et al.,
1999).
The results suggest that the structural changes are important
for the potential inhibition against the microorganisms B. sub-
tilis, E. coli, S. aureus and P. aeruginosa.  It was noticed that the
double bonds, as well as the phenolic group are not required for
the activity in the microorganisms tested. Nevertheless, the ester
group of the compound 3 is important for the inhibition and also
showed good activity. These results can encourage more studies
using this kind of compound for modiﬁcations aiming antimicrobial
activity.
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Table  1
Data of NMR  of 1–3 (CDCl3, 400 or 300a or 500b MHz, 1H and 100 or 75a or 125b MHz 13C, ı or ppm, J in Hz, * changeable).
1H NMR  1 1a 1b 2 3 3b 13CNMR 1 1a 1b 3b
1 1 120.9 121.0 123.8 125.9
2  7.68, s 7.77, s 7.77, s 7.76, s 7.83, s 7.84, s 2 130.0 130.5 130.5 134.5
3  3 127.0* 127.0 127.4* 127.0*
4  4 157.4 158.0 158.0 151.9
5  5 126.6* 127.0 127.0* 129.8*
6  7.68, s 7.77, s 7.77, s 7.76, s 7.83, s 7.83, s 6 130.0 130.5 130.5 134.5
1′ 3.33, d, J = 7.2 3.38, t = 7.0 3.38, t = 7.0 2.62, m 3.23, d, J = 7.2* 3.24, d, J = 6.3 1′ 29.0* 29.7 29.7* 28.9*
2′ 5.25, brt, J = 7.2 5.32, t = 7.0 5.32, t = 6.8 1.10–1.68, m 5.25, brt, J = 7.2 5.25, brt, J = 7.1* 2′ 120.8* 121.2 121.4* 120.9*
3′ 1.10–1.68, m 3′ 138.6 139.1 139.1 137.6
4′ 2.04, m 2.11, m 2.09, m 1.10–1.68, m 2.08, m 2.10, m 4′ 39.4 39.7 39.7 39.7
5′ 2.04, m 2.11, m 2.14, m 1.10–1.68, m 2.08, m 2.10, m 5′ 26.0 26.3 26.4 26.6
6′ 5.01, brt, J = 7.2 5.08, m 5.08, brt, J = 6.4 1.10–1.68, m 5.11, brt, J = 7.2 5.11, brt, J = 6.7 6′ 123.5 123.8 123.8 124.1
7′ 1.10–1.68, m 7′ 134.5 131.8 132.0 131.6
8′ 1.61, s 1.69, s 1.68, s 0.87, d, J = 6.6 1.60, s 1.60, s 8′ 25.3 25.7 25.7 25.7
9′ 1.71, s 1.77, s 1.77, s 0.97, d, J = 6.6 1.70, s 1.69, s 9′ 17.3 16.2 16.2 16.6
10′ 1.53, s 1.60, s 1.60, s 0.96, d, J = 6.6 1.69, s 1.67, s 10′ 15.9 17.9 17.7 17.7
1′′ 3.33, d, J = 7.2 3.38, t = 7.0 3.38, t = 7.0 2.62, m 3.24, d, J = 7.2* 3.24, d, J = 6.3 1′′ 29.3* 29.3 29.4* 28.8*
2′′ 5.25, brt, J = 7.2 5.32, t = 7.0 5.32, t = 6.8 1.10–1.68, m 5.25, brt, J = 7.2 5.24, brt, J = 7.2* 2′′ 121.0* 121.4 121.2* 120.8*
3′′ 1.10–1.68, m 3′′ 132.6 134.0 134.9 133.9
4′′ 1.71, s* 1.77, s 1.77, s 0.87, d, J = 6.6 1.70, s 1.70, s 4′′ 25.4 17.9 25.8 25.7
5′′ 1.70, s* 1.77, s 1.77, s 0.97, d, J = 6.6 1.76, s 1.76, s 5′′ 17.5 25.8 17.9 17.9
COO 170.4 172.0 172.2 170.7
CH3CO 2.33, s 2.33, s CH3CO 20.5
CH3CO 168.5
a Cruz et al. (2013).
b Dong et al. (1999).
Table 2
Activity against the microorganisms by myrsinoic A acid and derivatives.
Compounds Minimum inhibitory concentration (g/ml)
Bs Ec St Sa Sp Pa Ml  Ca Ck Ct
1 – – – – – – – – –
2  15.6 15.6 – 15.6 – 15.6 – – – –
3  62.5 125 – 125 – 125 – – – –
Vancomycin 0.047
Chloridrate of tetracycline 3.13 0.78 0.75 0.094 1.56 0.19
Nystatin 25.0 25.0 50.0
P s; Ec,  E
a us; Ca
A
s
t
t
J
d
t
r
C
A
2
a
R
Bositive controls: Vancomycin; Chloridrate of tetracycline; Nystatin; Bs,  Bacillus subtili
ureus;  Sp,  Streptococcus pyogenes; Pa,  Pseudomonas aeruginosa; Ml,  Micrococcus lute
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